Marker Therapeutics (MRKR) Total Liabilities (2010 - 2026)
Marker Therapeutics (MRKR) posted quarterly Total Liabilities of $3.6 million for Q1 2026, up 45.44% year-over-year from $2.5 million in Q1 2025, and up 59.97% quarter-over-quarter from $2.3 million in Q4 2025.
Marker Therapeutics (MRKR) Total Liabilities (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has reported Total Liabilities for 17 consecutive years, with $3.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 45.44% year-over-year to $3.6 million; the TTM figure through Mar 2026 stood at $3.6 million (up 45.44% YoY), while the FY2025 annual figure was $2.3 million, down 34.36% from the prior year.
- Total Liabilities grew to $3.6 million in Q1 2026 per MRKR's latest filing, from $2.3 million in the prior quarter.
- Across five years, Total Liabilities topped out at $24.3 million in Q2 2022 and bottomed at $2.0 million in Q2 2024.
- Historically, Total Liabilities has averaged $7.3 million across 5 years, with a median of $3.5 million in 2024.
- Annual changes were most pronounced in 2023 — Total Liabilities plunged 87.98% — and 2025, when it soared 116.88%.
- Marker Therapeutics' Total Liabilities stood at $14.8 million in 2022, then slumped by 79.25% to $3.1 million in 2023, then increased by 12.67% to $3.5 million in 2024, then sank by 34.36% to $2.3 million in 2025, then surged by 59.97% to $3.6 million in 2026.
- Business Quant data shows MRKR's Total Liabilities at $3.6 million in Q1 2026, $2.3 million in Q4 2025, and $3.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Marker Therapeutics | 23.95 Mn | 12.02 Mn | - | 2.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.64 Mn |
| Dec 31, 2025 | 2.27 Mn |
| Sep 30, 2025 | 3.35 Mn |
| Jun 30, 2025 | 4.28 Mn |
| Mar 31, 2025 | 2.50 Mn |
| Dec 31, 2024 | 3.46 Mn |
| Sep 30, 2024 | 3.46 Mn |
| Jun 30, 2024 | 1.97 Mn |
| Mar 31, 2024 | 2.30 Mn |
| Dec 31, 2023 | 3.07 Mn |
| Sep 30, 2023 | 2.78 Mn |
| Jun 30, 2023 | 2.92 Mn |
| Mar 31, 2023 | 12.03 Mn |
| Dec 31, 2022 | 14.82 Mn |
| Sep 30, 2022 | 18.51 Mn |
| Jun 30, 2022 | 24.29 Mn |
| Mar 31, 2022 | 19.25 Mn |
| Dec 31, 2021 | 24.15 Mn |
| Sep 30, 2021 | 19.66 Mn |
| Jun 30, 2021 | 17.23 Mn |